Hotspot Therapeutics Inc. has identified new E3 ubiquitin-protein ligase CBL-B inhibitors reported to be useful for the treatment of cancer.

New indazole pyridone compounds and their prodrugs have been patented by Bluejay Therapeutics Inc.

Prelude Therapeutics Inc. has described new CDK2/cyclin E2 and CDK4/cyclin D1 inhibitors reported to be useful for the treatment of cancer.

Amgen Inc. has disclosed new GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors potentially useful for the treatment of cancer have been described in a recent Scorpion Therapeutics Inc. patent.

Augusta University has patented NSAID derivatives acting as prostaglandin G/H synthase 1 (PTGS1; COX-1) and/or COX-2 inhibitors potentially useful for the treatment of inflammation and pain.

Work at Duke University has led to the discovery of prodrugs of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors potentially useful for the treatment of cancer and gram-negative bacterial infections.

Teon Therapeutics Inc. has identified new heterocyclic 5’-nucleotidase (CD73) inhibitors reported to be useful for the treatment of cancer.

Scientists at Foshan Ionova Biotherapeutics Co. Ltd., Guangdong Touchstone Translational Research Institute Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have described tricyclic compounds acting as cyclin-dependent kinase (CDK) inhibitors, particularly CDK1/cyclin B and/or CDK2/cyclin E1 and/or CDK4/cyclin D3 and/or CDK6/cyclin D3 inhibitors, reported to be useful for the treatment of cancer.

Oric Pharmaceuticals Inc. has divulged serine/threonine-protein kinase PLK4 (STK18) inhibitors reported to be useful for the treatment of cancer.